A recent report also showed that oral administration of LY603281-31-8, a small molecule inhibitor of GSK-3β and GSK-3α, increased bone formation, density and strength in an ovariectomized rat model [13] to the levels comparable to teriparatide (human PTH1-34), the only osteoanabolic drug that has recently been introduced into clinical practice for osteoporosis patients [39]. This evidence concerns the gene GSK3A and osteoporosis.